10:46 AM EDT, 07/01/2024 (MT Newswires) -- Longboard Pharmaceuticals ( LBPH ) said Monday the US Food and Drug Administration granted breakthrough therapy designation to its investigational drug bexicaserin to treat seizures associated with developmental and epileptic encephalopathies for patients two years and older.

"The FDA will work closely with us to provide guidance on subsequent development of bexicaserin to help us design and conduct a development program as efficiently as possible," Longboard Chief Medical Officer Randall Kaye said.

Longboard targets to begin its global phase 3 program later this year.

The breakthrough therapy designation is designed to speed up the development and review of treatments targeting serious or life-threatening diseases.

Price: 26.85, Change: -0.18, Percent Change: -0.67